| CatalogCode: | NB100-475 |
| ProductName: | PCNA Antibody |
| Product Description: | Mouse Polyclonal anti-PCNA |
| Clonality: | Polyclonal |
| Immunogen: | Recombinant fusion protein expressed in E.coli from PCNA interdomain connector loop protein. This immunogen is comprised of residues 107-196 of human PCNA. (The C-terminal portion of this antigen does not extend beyond the true IDCL of PCNA, and as such, also includes part of the PCNA D2E2 loop and the protein in between.) |
| Specificity: | PCNA is a homotrimeric protein that is involved in DNA replication and DNA repair. It serves as a processivity factor for DNA polymerase delta. It has also been shown to interact with several other proteins that are involved in DNA replication and repair, including replication factor C, DNA ligase I, XPG, FEN1 and p21. This particular antiserum was raised against the interdomain connector loop region of PCNA, which is the region of PCNA through which many of the protein-protein interactions occur. |
| CrossReactivity: | Cross-reacts with Human. Not yet tested in other species. |
| Packaging: | 0.05 ml Whole Mouse antisera. |
| Uses: | WB: Use at a dilution of 1/1000. Detects a band of approximately 31 kDa (predicted molecular weight: 31.3 kDa). Not tested in other applications.Optimal dilutions/concentrations should be determined by the end user. Use anti-mouse IgG secondary. |
| Localization: | Nuclear |
| Background: | PCNA is a marker for cells in early G1 phase and S phase of the cell cycle. It is found in the nucleus and is a cofactor of DNA polymerase delta. PCNA acts as a homotrimer and helps increase the processivity of leading strand synthesis during DNA replication. In response to DNA damage, PCNA is ubiquitinated and is involved in the RAD6 dependent DNA repair pathway. Two transcript variants encoding the same protein have been found for PCNA. Pseudogenes of this gene have been described on chromosome 4 and on the X chromosome. This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al. PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animal's cells produce the protein, which stimulates the animal's immune system to produce antibodies against that particular protein. A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein. Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein. |
| Storage: | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze thaw cycles. |
| Purity: | Whole antisera |
| Isotype: | IgG |
| Host_Name: | Mouse |
| Buffer: | Preservative: None Constituents: 10mM PBS. pH 7.4 |
| ListPrice: | 295 |
| AppSummary: | WB |
| SpeciesSummary: | Mu |
| ALTnames: | anti-Cyclin antibody, anti-DNA polymerase delta auxiliary protein antibody, anti-HGCN8729 antibody, anti-MGC8367 antibody, anti-polymerase delta accessory protein antibody, anti-Proliferating Cell Nuclear Antigen antibody |
| ProteinTarget: | PCNA antibody |
| PackageSize: | 0.05 ml |
| GeneralRef: | General / background references:Levin DS et al. Interaction between PCNA and DNA ligase I is critical for joining of Okazaki fragments and long-patch base-excision repair. Curr Biol 10:919-22 (2000). Warbrick E PCNA binding through a conserved motif. Bioessays 20:195-9 (1998). Warbrick E et al. Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair. Oncogene 14:2313-21 (1997). |